Advaxis is a clinical stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio engineered to secrete an antigen/adjuvant fusion protein s that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS HPV is currently being evaluated in four clinical trials for human papillomavirus HPV associated cancers: recurrent/refractory cervical cancer India , locally advanced cervical cancer GOG/NCI U.S. study, Clinical Trials.gov Identifier NCT , head amp neck cancer CRUK study, Clinical Trials.gov Identifier NCT , and anal cancer BrUOG study, Clinical Trials.gov Identifier NCT . Advaxis has over distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Quote | Advaxis (NASDAQ:ADXS)
Last: | $0.24 |
---|---|
Change Percent: | -18.45% |
Open: | $0.29 |
Close: | $0.24 |
High: | $0.2902 |
Low: | $0.2356 |
Volume: | 11,640,473 |
Last Trade Date Time: | 12/22/2021 04:55:26 pm |
News | Advaxis (NASDAQ:ADXS)
2024-06-27 14:14:36 ET Summary Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-d...
2024-05-09 16:18:02 ET More on Advaxis Financial information for Advaxis Read the full article on Seeking Alpha For further details see: Ayala Pharmaceuticals files Form 15 to voluntarily deregister and suspend reporting obligations
Message Board Posts | Advaxis (NASDAQ:ADXS)
Subject | By | Source | When |
---|---|---|---|
The only safe haven for $$$$ these days | hdwrsft | investorshub | 03/22/2023 5:15:04 PM |
What a turd. CEO Ken is running this | Ryguy008 | investorshub | 03/20/2023 2:35:37 PM |
Another massive bank shockingly failed. One day it's | hdwrsft | investorshub | 03/12/2023 6:03:14 AM |
Just think, in just another 7 years, and | hdwrsft | investorshub | 02/14/2023 2:26:10 PM |
If there is any justice in this universe, | HereToFightScams | investorshub | 01/11/2023 4:23:53 AM |
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) ...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...